ArticlePloS one2013
Multi-functional roles of chitosan as a potential protective agent against obesity.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 102 citations in OpenAlex.
- The effect of chitosan supplementation on liver function, hepatic steatosis predictors, and metabolic indicators in adults with non-alcoholic fatty liver disease: a randomized, double-blinded, placebo-controlled, clinical trial.Journal of health, population, and nutrition · 2025Trial
- Changes in gut microbiota following supplementation with chitosan in adolescents with overweight or obesity: a randomized, double-blind clinical trial.Diabetology & metabolic syndrome · 2025Article
- A Systematic Review and Meta-Analysis to Evaluate the Effects of Chitosan on Obesity Indicators.Food science & nutrition · 2024Review
- Bioactive carbohydrate polymers from marine sources as potent nutraceuticals in modulating obesity: a review.Food science and biotechnology · 2024Review
- Anti-Obesity Effects of Chitosan and Its Derivatives.Polymers · 2023Review
- Gut commensals and their metabolites in health and disease.Frontiers in microbiology · 2023Review
- In Vivo and In Silico Investigation of the Anti-Obesity Effects ofInternational journal of molecular sciences · 2022Article
- Biomaterial-Based Therapeutic Strategies for Obesity and Its Comorbidities.Pharmaceutics · 2022Review
- Selenium-Enriched Mushroom Powder Enhances Intestinal Health and Growth Performance in the Absence of Zinc Oxide in Post-Weaned Pig Diets.Animals : an open access journal from MDPI · 2022Article
- Mollification of Doxorubicin (DOX)-Mediated Cardiotoxicity Using Conjugated Chitosan Nanoparticles with Supplementation of Propionic Acid.Nanomaterials (Basel, Switzerland) · 2022Article
- Effects of Dietary Supplementation with Mushroom or Vitamin DAnimals : an open access journal from MDPI · 2021Article
- Synergistic effect of curcumin and chitosan nanoparticles on nano-hydroxyapatite-induced reproductive toxicity in rats.Environmental science and pollution research international · 2021Article
- Fungal Dysbiosis Correlates with the Development of Tumor-Induced Cachexia in Mice.Journal of fungi (Basel, Switzerland) · 2020Article
- Current Evidence to Propose Different Food Supplements for Weight Loss: A Comprehensive Review.Nutrients · 2020Review
- Article
- Beneficial Metabolic Effects of Chitosan and Chitosan Oligosaccharide on Epididymal WAT Browning and Thermogenesis in Obese Rats.Molecules (Basel, Switzerland) · 2019Article
- Nutritionist and obesity: brief overview on efficacy, safety, and drug interactions of the main weight-loss dietary supplements.International journal of obesity supplements · 2019Review
- Peptides and Peptidomimetics as Potential Antiobesity Agents: Overview of Current Status.Frontiers in nutrition · 2019Review
- Chitin and Its Effects on Inflammatory and Immune Responses.Clinical reviews in allergy & immunology · 2018Review
- Combined effects of chitosan and microencapsulatedAnimal nutrition (Zhongguo xu mu shou yi xue hui) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chitosan, a natural polysaccharide comprising copolymers of glucosamine and N-acetylglucosamine, has been shown to have anti-obesity properties. Two experiments (Exp. 1 and Exp. 2) were performed to determine the role of chitosan on dietary intake, body weight gain, and fat deposition in a pig model, as well as identifying potential mechanisms underlying the anti-obesity effect of chitosan. In Exp. 1, the nutrient digestibility experiment, 16 pigs (n = 4/treatment) were randomly allocated to one of four dietary treatments as follows: 1) basal diet; 2) basal diet plus 300 ppm chitosan; 3) basal diet plus 600 ppm chitosan; 4) basal diet plus 1200 ppm chitosan. The main observation was that crude fat digestibility was lower in the 1200 ppm chitosan group when compared with the control group (P<0.05). In Exp. 2, a total of 80 pigs (n = 20/treatment) were offered identical dietary treatments to that offered to animals in Exp. 1. Blood samples were collected on day 0, day 35 and at the end of the experiment (day 57). Animals offered diets containing 1200 ppm chitosan had a lower daily dietary intake (P<0.001) and body weight gain (P<0.001) from day 35 to 57 when compared with all the other treatment groups. Animals offered diets containing 1200 ppm chitosan had a significantly lower final body weight (P<0.01) when compared with all the other treatment groups. The decreased dietary intake observed in the 1200 ppm chitosan group was associated with increased serum leptin concentrations (P<0.001) and a decrease in serum C-reactive protein (CRP) concentrations (P<0.05). In conclusion, the results of this study highlight novel endocrine mechanisms involving the modulation of serum leptin and CRP concentrations by which chitosan exhibits anti-obesity properties in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.